Immune checkpoint inhibitors (ICIs), such as anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies, show promising efficacy in a wide range of cancer types and represent a breakthrough in cancer therapy1. The gene discussed is CD274; the disease is cancer.